Amarin Corp Plc (AMRN)

[Biobillionair]

Vascepa and Pediactric Orphan status

Vascepa and Amarin have enough information to apply for a very impressive exclusivity status.

In July 2008, the AAP released updates to their lipid screening and cardiovascular health recommendations.[3] The more recent guidelines agree with most of the NCEP guidelines but are more specific, recommending precise ages and more aggressive repeat testing in high-risk patients. The guidelines state that pediatric patients with a family history of dyslipidemia or premature cardiovascular disease (defined the same as NCEP), those with an unknown family history, or those with risk factors including lifestyle (smoking, physical inactivity), metabolic disorders (eg, low HDL-C, diabetes mellitus), and hypertension should be screened with a fasting lipid profile. Initial screening should take place between age 2 and 10 years; if levels are within normal limits for age, repeat testing does not need to be obtained for 3-5 years.
-------------------
This market is more lucrative than "Marine", and if embraced would have extreme Marketing potential.

Williams